MaxCyte Latest News

MaxCyte announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes.

MaxCyte’s Senior Director of Innovation and Business Development Sean Menarguez shares the future of off-the-shelf T-cell therapies in this latest piece from BioProcess Insider.
Learn more about:
How next-generation, non-viral T-cell platforms are shaping the landscape for scalable, allogeneic therapies
Why electroporation technology is enabling high-efficiency, non-viral cell engineering at clinical scale
What’s next for bridging innovative, non-viral research with real-world patient impact

MaxCyte’s Flow Electroporation® Technology will support the development of gamma delta T cell therapy gene edited programs

MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies

Andrew Mancini from MaxCyte dives into data supporting a novel strategy for treating patients with sickle cell disease and the tools and technologies required to facilitate high-efficiency gene editing. Read more>>

MaxCyte is thrilled to have joined forces with Ori Biotech, to help improve the scalability, efficiency, and accessibility of gene-edited cell therapies! By integrating our ExPERT Electroporation platform with Ori’s IRO manufacturing system, our collaboration aims to: improve gene-edited T cell yield, shorten manufacturing timelines, support a seamless path from R&D to GMP production. Read more.

When research funding is limited, every decision matters. In this issue, read how MaxCyte is reducing inefficiencies in gene and cell therapy as well as assay development. Find on-demand and upcoming resources to help save time and funding in your work.

From his recent presentation during Technology Networks’ Cell and Gene Therapy 2025 Symposium, MaxCyte’s Dr. Andrew Guy Mancini explores the rapid evolution of engineered cell therapies, and what’s next for the field. From the rise of non-viral delivery methods to the shift toward allogeneic approaches, Dr. Mancini highlights how developers are tackling complexity, scalability, and cost to bring next-generation therapies to more patients.

From advances in cell therapy to changes at MaxCyte®, the past few months have been busy. Through it all, we remain committed to helping you solve the toughest cell engineering challenges with our proven ExPERT™ platform and trusted support. This issue of MaxCyte Minutes Newsletter has a lot in store! Let’s dive in. Read more. . . .

TG Therapeutics to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases